Sana Biotechnology Investor Relations Material

Sana Biotechnology Inc. is a biotechnology company focusing on the development of engineered cells as medicines. The company focuses on both ex vivo and in vivo cell engineering platforms to address a variety of therapeutic areas with significant unmet needs, including oncology, diabetes, central nervous system disorders, and autoimmune diseases among others. Sana Biotechnology's approach involves the use of cutting-edge technologies such as CRISPR for gene editing and their proprietary platforms, Fusogen for in vivo cell engineering, and a hyperimmune platform for ex vivo cell engineering. They are actively investigating potential treatments for conditions such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, multiple myeloma, and diabetes, to name a few. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.